Edwards Heart Valve Snags Extra Patent Review Time
Published Date: 6/25/2025
Notice
Summary
The FDA has set the official review period for the EDWARDS SAPIEN 3 ULTRA RESILIA heart valve device, helping the makers apply for extra patent time. This means the company can potentially extend their patent, giving them more time to protect their invention and possibly earn more money. Patients and competitors should watch for changes in patent status and market availability.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
FDA Sets Review Period for Valve
The FDA has determined the regulatory review period for the EDWARDS SAPIEN 3 ULTRA RESILIA premarket approval supplement (PMA 140031, S-141). This determination allows the device maker to submit applications to the U.S. Patent and Trademark Office to seek an extension of a patent that claims this medical device.
Patients, Competitors Should Watch
The notice says patients and competitors should watch for changes in the device's patent status and market availability after the FDA set the review period for EDWARDS SAPIEN 3 ULTRA RESILIA (PMA 140031, S-141). Changes in patent status could affect who sells the device and how broadly it is available.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-17215, Evaluation of Therapeutic Equivalence; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Evaluation of Therapeutic Equivalence." This guidance explains FDA's thinking on therapeutic equivalence evaluations and therapeutic equivalence codes (TE codes). FDA's therapeutic equivalence evaluations are listed for multisource prescription drug products approved under the Federal Food, Drug, and Cosmetic Act (FD&C Act) in the active section of the "Approved Drug Products With Therapeutic Equivalence Evaluations" (commonly known as the Orange Book). These therapeutic equivalence evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. This guidance finalizes the draft guidance of the same title issued in July 2022.
2026-17229, Food and Drug Administration Modernization Act of 1997: Modifications to the List of Recognized Standards, Recognition List Number: 066
The Food and Drug Administration (FDA or the Agency) is announcing a publication containing modifications the Agency is making to the list of standards FDA recognizes for use in premarket reviews (FDA Recognized Consensus Standards). This publication, entitled "Modifications to the List of Recognized Standards, Recognition List Number: 066" (Recognition List Number: 066), will assist manufacturers who elect to declare conformity with consensus standards to meet certain requirements for medical devices.
2026-17222, Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of additional draft and revised draft product-specific guidances. The draft guidances provide product-specific recommendations on, among other things, the design of bioequivalence (BE) studies to support abbreviated new drug applications (ANDAs). In the Federal Register of June 11, 2010, FDA announced the availability of a guidance for industry titled "Bioequivalence Recommendations for Specific Products" that explained the process that would be used to make product-specific guidances available to the public on FDA's website. The draft guidances identified in this notice were developed using the process described in that guidance.
Previous / Next Documents
Previous: 2025-11602, Determination of Regulatory Review Period for Purposes of Patent Extension; AGAMREE
The FDA has officially set the review period for AGAMREE, a human drug product, so its patent can be extended. This helps the company get extra time to protect their invention after the long approval process. If you’re involved in drug patents or development, this timing update could impact your plans and profits.
Next: 2025-11604, Determination of Regulatory Review Period for Purposes of Patent Extension; FILSPARI
The FDA has officially set the review period for FILSPARI, a human drug product, so its patent can be extended. This means the company behind FILSPARI gets more time to protect their invention and keep competitors at bay. If you’re in the pharma world, watch for this patent extension—it could impact when generics hit the market and affect drug prices.